Back to search
Wet Age-related Macular Degeneration
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Wet Age-related Macular Degeneration trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients w…
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a sma…
In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration \[AM…
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as af…
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-…
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.